3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
177
Lung Neoplasms
59
Neoplasms
24
Neoplasm Metastasis
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Mesothelioma, Malignant
12
Carcinoma
11
Colorectal Neoplasms
10
Mesothelioma
9
Meningeal Carcinomatosis
8
Melanoma
7
Brain Neoplasms
7
Pancreatic Neoplasms
6
Adenocarcinoma of Lung
6
Advanced Solid Tumors
5
Uterine Cervical Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Non-squamous Non-small Cell Lung Cancer
3
Neoplasms by Histologic Type
3
NSCLC
3
Lung Diseases
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Bronchogenic
3
Adenocarcinoma
3
Thoracic Neoplasms
2
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
25
130-nm albumin-bound paclitaxel
24
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
Doxorubicin
20
olaparib
19
Taxes
19
Biopsy
19
Albumin-Bound Paclitaxel
19
Drug Therapy
16
atezolizumab
13
Nivolumab
13
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Pemetrexed
×
1 year
×
Clear all
NCT03396445
2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1
Completed
182 enrolled
36 charts